Mural Oncology plc (MURA) Financials
Newest figures come from the 10-Q for Q3 FY2025, filed Nov 6, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MURA SEC filings page.
This page shows Mural Oncology plc (MURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Mural Oncology plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Mural Oncology plc passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Mural Oncology plc reported a net loss of $128.5M while operations used $128.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Mural Oncology plc's EBITDA was -$3.2M in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 90.5% from the same quarter a year earlier. Against the prior quarter it is up 93.4%.
Mural Oncology plc reported -$3.7M in net income in Q3 2025. This represents an increase of 88.3% from the same quarter a year earlier. Against the prior quarter it is up 92.3%.
Mural Oncology plc earned -$0.21 per diluted share (EPS) in Q3 2025. This represents an increase of 88.8% from the same quarter a year earlier. Against the prior quarter it is up 92.4%.
Not reported for Q3 2025.
Cash & Balance Sheet
Mural Oncology plc recorded an outflow of $18.5M in free cash flow in Q3 2025, representing a cash shortfall after capex. This represents an increase of 38.6% from the same quarter a year earlier. Against the prior quarter it is up 41.1%.
Mural Oncology plc held $58.9M in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Margins & Returns
Mural Oncology plc's ROE was -6.7% in Q3 2025, measuring profit generated per dollar of shareholder equity. This is up 11.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 74.9 percentage points.
Not reported for Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
Capital Allocation
Mural Oncology plc reported no capital expenditure in Q3 2025. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q3 2025.
Not reported for Q3 2025.
MURA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $23.3M-15.5% | $27.4M+2.1% | N/A | $27.6M-31.6% | $27.5M-35.2% | $26.9M-33.5% | N/A |
| SG&A Expenses | $8.3M+26.7% | $8.1M+20.0% | $7.0M-2.9% | N/A | $6.5M+9.3% | $6.7M+42.3% | $7.2M+91.3% | N/A |
| Operating Income | -$4.0M+88.4% | -$48.8M-42.5% | -$34.4M-1.0% | N/A | -$34.1M+26.4% | -$34.3M+27.5% | -$34.0M+22.9% | N/A |
| EBITDA | -$3.2M+90.5% | -$47.7M-43.0% | -$33.5M-1.0% | N/A | -$33.2M+27.1% | -$33.4M+28.3% | -$33.2M+23.9% | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0-100.0% | $0-100.0% | $0-100.0% | N/A |
| Net Income | -$3.7M+88.3% | -$48.0M-52.0% | -$33.1M-7.2% | N/A | -$31.8M+38.1% | -$31.6M+36.6% | -$30.9M+34.0% | N/A |
| EPS (Basic) | -$0.21+88.8% | -$2.78-49.5% | -$1.93-4.9% | -$2.01+43.7% | -$1.87+39.1% | -$1.86+38.2% | -$1.84+33.8% | -$3.57-22.7% |
| EPS (Diluted) | -$0.21+88.8% | -$2.78-49.5% | -$1.93-4.9% | -$2.01+43.7% | -$1.87+39.1% | -$1.86+38.2% | -$1.84+33.8% | -$3.57-22.7% |
| Diluted Shares (Avg) | 17M+1.7% | 17M+2.0% | 17M+2.2% | N/A | 17M+2.0% | 17M+1.4% | 17M+0.6% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
MURA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $65.8M-67.7% | $87.6M-62.7% | $132.1M-49.9% | $169.4M-43.9% | $203.3M+573.0% | $234.9M | $263.5M | $301.7M+794.1% |
| Current Assets | $62.2M-66.2% | $81.6M-61.7% | $117.7M-50.9% | $152.9M-44.9% | $183.8M+3604.8% | $213.1M | $239.4M | $277.3M+5657.5% |
| Cash & Equivalents | $58.9M-47.0% | $77.1M-36.6% | $106.7M-0.5% | $115.5M-57.4% | $111.0M | $121.6M | $107.3M | $270.9M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.6M-63.7% | $28.8M-5.2% | $24.2M-15.3% | $28.9M-23.8% | $29.1M-21.5% | $30.4M | $28.6M | $37.9M-31.5% |
| Current Liabilities | $10.5M-57.7% | $28.4M+15.4% | $23.2M+9.0% | $26.2M-9.7% | $24.9M-5.7% | $24.6M | $21.2M | $29.0M-30.2% |
| Non-Current Liabilities | $42K-99.0% | $354K-93.8% | $1.0M-85.8% | $2.7M-69.7% | $4.2M-60.5% | $5.7M | $7.3M | $8.9M-35.6% |
| Total Equity | $55.2M-68.3% | $58.8M-71.3% | $107.9M-54.1% | $140.5M-46.7% | $174.1M+2626.7% | $204.6M+2099.1% | $234.9M+2643.9% | $263.8M+1318.2% |
| Retained Earnings | -$244.2M-95.2% | -$240.5M-157.7% | -$192.5M-211.6% | -$159.4M-416.5% | -$125.1M | -$93.3M | -$61.8M | -$30.9M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
MURA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.5M+38.6% | -$31.4M-6.8% | -$36.8M+1.4% | -$31.8M+25.6% | -$30.1M+40.4% | -$29.4M+35.2% | -$37.3M+33.0% | -$42.7M-12.8% |
| Depreciation & Amortization | $800K-11.1% | $1.1M+22.2% | $851K+0.6% | $868K+41.6% | $900K+12.5% | $900K+28.6% | $846K+59.6% | $613K |
| Stock-Based Compensation | $109K-89.4% | -$1.1M-194.2% | $513K-76.7% | N/A | $1.0M-65.5% | $1.2M-62.1% | $2.2M-20.1% | N/A |
| Capital Expenditures | $0-100.0% | $5K | $10K-81.8% | $23K-98.0% | $14K-98.8% | $0-100.0% | $55K-86.2% | $1.2M+723.8% |
| Free Cash Flow | -$18.5M+38.6% | -$31.4M-6.8% | -$36.8M+1.6% | -$31.8M+27.6% | -$30.1M+41.7% | -$29.4M+36.2% | -$37.4M+33.4% | -$43.9M-15.4% |
| Investing Cash Flow | $0-100.0% | $1.8M-95.9% | $28.0M+122.5% | $36.2M+3174.2% | $19.3M+1756.3% | $43.7M+6252.5% | -$124.5M-31191.5% | -$1.2M-723.8% |
| Financing Cash Flow | $0-100.0% | $0 | $28K | $0-100.0% | $196K-99.6% | $0-100.0% | $0-100.0% | $315.0M+728.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MURA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -6.7%+11.5pp | -81.6%-66.2pp | -30.7%-17.5pp | N/A | -18.2% | -15.4% | -13.2% | N/A |
| Return on Assets | -5.6%+10.0pp | -54.8%-41.4pp | -25.1%-13.4pp | N/A | -15.6%+154.2pp | -13.4% | -11.7% | N/A |
| Current Ratio | 5.90-1.5x | 2.87-5.8x | 5.08-6.2x | 5.84-3.7x | 7.38+7.2x | 8.65 | 11.27 | 9.56+9.4x |
| Debt-to-Equity | 0.190.0x | 0.49+0.3x | 0.22+0.1x | 0.21+0.1x | 0.17 | 0.15 | 0.12 | 0.14 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Mural Oncology plc MURA | FY2024 | N/A | -$128.5M | N/A | $35.2M | — |
| Mersana Therapeutics, Inc. MRSN | FY2024 | $40.5M | -$69.2M | N/A | $145.4M | 54/100 |
| Senti Biosciences Holdings, Inc. SNTI | FY2025 | $22K | -$61.4M | N/A | $9.8M | — |
| Xilio Therapeutics, Inc. XLO | FY2025 | $43.8M | -$35.0M | -80.0% | $59.6M | 87/100 |
| Jasper Therapeutics, Inc. JSPR | FY2025 | N/A | -$76 | N/A | $19.0M | — |
| LAVA Therapeutics N.V. LVTX | FY2024 | $12.0M | -$25.1M | N/A | $45.8M | 53/100 |
Where Mural Oncology plc Ranks
Frequently Asked Questions
Is Mural Oncology plc profitable?
No, Mural Oncology plc (MURA) reported a net income of -$128.5M in fiscal year 2024.
What is Mural Oncology plc's EBITDA?
Mural Oncology plc (MURA) had EBITDA of -$134.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mural Oncology plc's return on equity (ROE)?
Mural Oncology plc (MURA) has a return on equity of -91.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Mural Oncology plc's free cash flow?
Mural Oncology plc (MURA) recorded an outflow of $128.6M in free cash flow during fiscal year 2024. This represents a 34.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Mural Oncology plc's operating cash flow?
Mural Oncology plc (MURA) recorded an outflow of $128.5M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Mural Oncology plc's total assets?
Mural Oncology plc (MURA) had $169.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Mural Oncology plc's capital expenditures?
Mural Oncology plc (MURA) invested $92K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Mural Oncology plc spend on research and development?
Mural Oncology plc (MURA) invested $110.7M in research and development during fiscal year 2024.
What is Mural Oncology plc's current ratio?
Mural Oncology plc (MURA) had a current ratio of 5.84 as of fiscal year 2024, which is generally considered healthy.
What is Mural Oncology plc's debt-to-equity ratio?
Mural Oncology plc (MURA) had a debt-to-equity ratio of 0.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mural Oncology plc's return on assets (ROA)?
Mural Oncology plc (MURA) had a return on assets of -75.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does Mural Oncology plc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, Mural Oncology plc (MURA) held $115.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $128.5M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Mural Oncology plc's Piotroski F-Score?
Mural Oncology plc (MURA) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mural Oncology plc's earnings high quality?
Mural Oncology plc (MURA) reported a net loss of $128.5M while operations used $128.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.